Safety and efficacy data from a phase 1 multicenter study evaluating rapcabtagene autoleucel, an investigational ...
Kelonia Therapeutics' KLN-1010 has shown promising early results in a phase 1 trial for relapsed or refractory multiple ...
Researchers from the Keck School of Medicine of USC have developed a new type of chimeric antigen receptor (CAR) T cell that ...
A cutting-edge base-edited CAR T-cell therapy is opening a revolutionary new frontier for patients battling aggressive T-cell ...
CAR T-cell therapy, which transforms patients’ own immune cells into cancer-fighting warriors, has been extremely effective ...
T cell therapy anitocabtagene autoleucel (anito-cel) continued to show strong results in treating relapsed/refractory ...
The researchers argue that their findings, published in Scientific Reports, could help clinicians anticipate which patients ...
A new treatment using genome-edited immune cells, developed by scientists at UCL (University College London) and Great Ormond ...
Poster presentation highlights promising results from Phase 1b/2 TENACITY-01 study of CTD402 in T-Cell and myeloid leukemiasFindings underscore ...
The CAR T Vision Steering Committee members wish to double the number of eligible patients receiving chimeric antigen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback